Aclaris Therapeutics (ACRS) Reports Q4 Loss of $0.28/Share

Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 EPS of ($0.28), versus ($1.76) reported last year.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• SolarEdge (SEDG) PT Lowered to $31 at Jefferies, 'We see shares as an unappealing short, not a compelling long'
• Dollar Tree (DLTR) Tops Q2 EPS by $1.59, Beats on Revenue; Offers FY Guidance
• Best Buy (BBY) Tops Q2 EPS by 12c, Offers Guidance